Parkinson's disease patients with rapid eye movement (REM) sleep behaviour disorder (RBD). We investigated the frequency of nocturnal vocalization and other sleep problems in patients with pure autonomic failure (PAF) and compared the results with idiopathic Parkinson's disease (IPD) and dementia with Lewy bodies (DLB). We interviewed consecutive patient-caregiver pairs with PAF (n = 13), IPD (n = 200) and DLB (n = 19), and ischaemic stroke patients (controls, n = 43). Nocturnal vocalization was similarly frequent in PAF, IPD and DLB. Other dream enactments and vivid dreams also were more frequent in PAF, IPD and DLB compared with controls. Excessive night-time awakenings and daytime sleepiness were frequent in IPD but rare in PAF and controls. Clinical manifestation of sleep disturbances, at least of RBD-like symptoms including nocturnal vocalization and other dream enactments, may occur in PAF, as in IPD and DLB.
Introduction
Pure autonomic failure (PAF), as well as idiopathic Parkinson's disease (IPD) and dementia with Lewy bodies (DLB), shows Lewy bodies and Lewy neurites inside nerve cells of the brainstem, limbic area, neocortex and sympathetic ganglia. 1 -3 These diseases are, therefore, assumed to be three phenotypes of a single disorder. In a previous study, we reported that these diseases showed a common reduction in the cardiac uptake of 123 I-metaiodobenzylguanidine (MIBG), 4 indicative of degenerated cardiac postganglionic sympathetic nerves. 5 Rapid eye movement (REM) sleep behaviour disorder (RBD) is often a complication in IPD and DLB 3,6,7 and may precede IPD motor symptoms. 7 -9 Vocalization during sleep frequently occurs in IPD with RBD 7,10 and may provide a diagnostic indicator of RBD. In the present study we investigated the frequencies of nocturnal vocalization and other sleep problems in patients with PAF, and compared the results with those for patients with IPD and DLB, and a control group. 12 Patients with PAF may later develop IPD or multiple system atrophy (MSA). In order to select PAF patients with Lewy body pathology, they all underwent myocardial 123 I-MIBG scintigraphy and those with a marked reduction in uptake of 123 I-MIBG were enrolled in this study. Patients with MSA usually show normal or only slightly reduced 123 I-MIBG uptake. 13, 14 Control subjects comprised consecutive patients with acute ischaemic stroke who visited Okayama Kyokuto Hospital over the same time period.
Patients and methods PATIENTS
Patients who presented dementia or a medical or mental disorder just before their most recent stroke, which may affect sleep, were omitted from the study. This study was approved by the Ethical Committee of Okayama Kyokuto Hospital. Informed consent was obtained in every case prior to the study.
EVALUATION OF SLEEP PROBLEMS
Patient-caregiver pairs were assessed for the following sleep states: 1, difficulty in falling asleep; 2, number of awakenings from sleep; 3, excessive daytime sleepiness; 4, vocalization during sleep; 5, other enactments of dreams; 6, vivid dreams; and 7, restless legs syndrome (RLS). For control subjects, the sleep status just before the latest stroke was obtained. Those under hypnotic or neuroleptic medication before sleep were categorized as having difficulty in falling asleep. Waking up more than three times a night was deemed abnormal. Daytime somnolence, nocturnal vocalization and vivid dreams were counted as abnormal when the patient and/or the caregiver recognized it as being unusual. The RLS diagnosis was based on criteria reported by Walters et al. 15 When patient-caregiver pairs could not tell the state of vocalization, they were excluded from the study. If they could not provide a reliable answer to items other than vocalization, then 'no data' was recorded and they were excluded from statistical evaluation.
STATISTICAL ANALYSIS
Intergroup differences in age and duration of illness were evaluated by one-way analysis of variance (ANOVA) followed by Sheffe's test post-hoc. Intergroup differences in the frequency of sleep-related problems were analysed by χ 2 -test. Differences in the Hoehn and Yahr stages between IPD and DLB patients was determined by a Mann-Whitney U-test. A P-value < 0.05 was considered statistically significant.
Results
Thirteen patient-caregiver pairs (11 men, two women) with PAF, 200 (84 men, 116 women) with IPD, 19 (nine men, 10 women) with DLB and 43 control subjects (30 men, 13 women) provided their sleep status. Mean age ± SD was 70.0 ± 5.5 years for PAF, 70.3 ± 9.4 years for IPD, 76.2 ± 6.8 years for DLB and 69.0 ± 10.3 years for controls. ANOVA found no significant between-group differences in age. Mean disease duration ± SD was 2.0 ± 1.9 years for PAF, 5.0 ± 4.6 years for IPD and 2.0 ± 2.1 years for DLB. Duration was significantly longer in IPD patients than in those with PAF (P < 0.05) or DLB (P < 0.05).
The mean Hoehn and Yahr stage for IPD patients at on state was 2.8 and at off state was 2.9, whereas they were 3.1 and 3.1 for DLB, respectively. This was significantly higher for DLB patients at on state (P < 0.05), but was not significant at off state. The numbers of patients and frequencies Table 1 and Fig. 1 The frequency of vivid dreams was also significantly higher in the PAF, IPD and DLB groups (38.5%, 28.0% and 27.8%, respectively) compared with the controls (4.7%) (χ 3 2 = 11.8, P < 0.05). The frequency of difficulty in falling asleep among the patient groups was similar to that of the controls. The frequency of awakenings was the same in the PAF (7.7%) and DLB (26.3%) groups as in the controls (9.3%), whereas it was significantly higher in the IPD group (27.4%; χ 1 2 = 6.3, P < 0.05 vs controls). The frequency of excessive daytime sleepiness was similar in the PAF group (7.7%) and controls (4.7%), whereas it was significantly higher than the controls in IPD (36.1%; χ 1 2 = 16.4, P < 0.05) and DLB (42.1%; χ 1 2 = 13.7, P < 0.05). The percentage of patients with RLS in the IPD group was 10.0%, and the prevalence did not differ significantly among the three disease groups and the control subjects (2.4%).
Discussion
In the present study, patients with PAF had nocturnal vocalization as often as those with IPD and DLB. Vocalization during sleep is a frequent symptom of IPD with RBD, the reported incidence ranging from 85 to 100%. 7,10 Plazzi et al. 16 found that RBD differentiated PAF from MSA, however, because nocturnal vocalization may indicate RBD, our results do not support that conclusion. Instead, we suggest that PAF may complicate RBD to the same extent as IPD and DLB. PAF is recognized as a localized clinical manifestation of the peripheral autonomic nervous system. IPD shows extrapyramidal symptoms derived from nigral degeneration but also has autonomic, medullary and neocortical involvement. The main lesion in DLB is in the limbic structure, but the brain stem, sensorimotor cortex and autonomic nervous system are also involved. 2 Hague et al. 1 reported that patients with PAF have Lewy bodies in the central nervous system as do those with IPD and DLB. PAF, IPD and DLB appear to be three phenotypes of a single disorder: PAF sometimes develops into PD or DLB. 17 Braak et al. 2 hypothesized that the pathological process of IPD starts in the medulla, develops upward to the substantia nigra, then to the cerebral cortex. Wakabayashi et al. 18 reported involvement of the visceral autonomic nervous system with inclusions identical to the Lewy bodies seen in patients with PD. According to the staging system of Braak et al., 2 the pathological processes of these diseases may initially start peripherally, then pass via the brain stem to the neocortex.
RBD may be a potential early marker of PD: 19 its reported frequency in PD ranges from 31 to 47%. 6,7,20 RBD preceded the emergence of motor symptoms in 27%, 38% or 52% of PD patients with RBD. 7 -9 Several such patients are reported to have a Lewy body pathology identical to that of IPD. 21 The critical lesion in RBD is in the dorsal midbrain and pons. 22 As to the other sleep-related problems investigated, the frequency of difficulty in falling asleep did not differ between the disease and control groups. Frequent awakenings were observed in IPD but not in PAF patients. Sleep interruption in PD is caused, in part, by problems associated with PD symptoms, such as pain and stiffness, difficulty in turning and medication-induced arousal. 23 Lack of motor symptoms and, therefore, no need of dopaminergic replacement therapy in PAF may prevent frequent night-time waking. Excessive daytime sleepiness was frequent in IPD and DLB, but not in PAF patients and the control subjects. Daytime somnolence may result from a disturbed sleep arousal system involving dopaminergic, noradrenergic, serotonergic and cholinergic systems in the brainstem, basal ganglia, limbic and cerebral cortices. 24 Anti-parkinsonian drugs, and/or insomnia due to frequent urination, pain, akinesia, tremor, depression, anxiety and psychosis also may cause daytime sleepiness. In PD, disease severity, duration and medications are reportedly the main causes of daytime sleepiness. 23,25 -27 Our patients with PAF had no motor impairment or history of taking anti-parkinsonian drugs. As to cognitive impairment, the Mini-Mental State Examination score has not been shown to be decreased in PAF, but it was in IPD and more markedly decreased in DLB. 4 The extent of upward involvement of the CNS beyond the midbrain appears to correspond mainly to enhanced daytime sleepiness.
The frequency of RLS did not differ among the three disease groups and controls. The RLS frequency for IPD patients in the present study was 10.0%, which is lower than the 20.8% reported by Ondo et al., 28 and closer to the 12% prevalence rate reported for Japan. 29 Ondo et al. 28 reported that PD might be a risk factor for RLS and that a secondary RLS could occur after the onset of PD. Our results indicate that RLS is not necessarily associated with the Lewy body pathology that corresponds to PAF. Current evidence does not show more than a casual association between PD and RLS. 30 As a result of the small number of RLS patients in the groups, other than in the IPD group, further study is needed to provide a definite answer.
In conclusion, the results of the present study suggest that PAF shares nocturnal vocalization with IPD and DLB, perhaps because these disorders involve the same extent of brainstem lesions critical to RBD. In contrast, frequent excessive daytime sleepiness in IPD and DLB, but not in PAF, suggests only slight involvement of cerebral structures in PAF as compared with IPD and DLB. Our findings indicate that PAF frequently manifests vocalization or various sleep problems indicative of RBD or brainstem involvement. A polysomnographic study is needed to confirm whether RBD is a complication of PAF.
